We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Qiagen Acquires Eppendorf's Reagent Business

By Labmedica staff writers
Posted on 18 Jan 2006
A co-development and co-marketing alliance has been announced by Qiagen N.V. More...
(Venlo, The Netherlands) and Eppendorf (Hamburg, Germany), whereby Qiagen has acquired the nucleic acid sample preparation kit and polymerase chain reaction (PCR) reagent business of Eppendorf. Financial terms were not disclosed.

The alliance is designed to link two strong brands and product lines in the industry to ensure the highest compatibility of their products, which target research, applied testing, and molecular diagnostics.

Eppendorf's reagent business includes the 5-Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytic and nucleic acid amplification consumables and also a promising pipeline of technologies for nucleic acid handling, separation, purification, and amplification.

Qiagen has developed a comprehensive portfolio of proprietary, consumable products for nucleic acid and protein separation, purification and handling, as well as automated instrumentation. Through the alliance, the two companies intend to focus on improving biologic sample management and analysis. They believe the availability of combined and optimized products should create significant benefits for customers in research, applied testing, and molecular diagnostics.

"Functionalizing Eppendorf solutions with Qiagen's biological and chemical preanalytical capabilities will allow both partners to take ease-of-use and capabilities of molecular biology methods to new levels,” said Peer Schatz, CEO of Qiagen.



Related Links:
Qiagen
Eppendorf

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.